RT Journal Article SR Electronic T1 Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.200369 DO 10.3899/jrheum.200369 A1 Scuccimarri, Rosie A1 Sutton, Evelyn A1 Fitzcharles, Mary-Ann YR 2020 UL http://www.jrheum.org/content/early/2020/04/01/jrheum.200369.abstract AB Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].